Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S. Read more
Inhibrx Receives FDA Orphan-Drug Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Read more
Epsilogen Announces Completion of Oversubscribed £30.75 Million ($41.20 Million) Series B Financing Read more
Quoin Pharmaceuticals Extends Exclusive Distribution Agreement with ER-Kim for its Lead Asset, QRX003, for Netherton Syndrome Read more
GC Labs and Two Clinical Diagnostic Companies Enter the Collaboration for the New Lab Testing Service Read more
Rondo Therapeutics Closes $67 Million Series A Financing to Advance Next-Generation Immuno-Oncology Platform for Solid Tumors Read more
Ascletis Announces Submission of Marketing Authorization Applications for Ritonavir in Eight Additional European Countries Read more